Le choix thérapeutique : médicaments du psoriasis et grossesse avant, pendant et après la grossesse.

Eur J Dermatol

Université Claude-Bernard Lyon I, Hospices Civils de Lyon, service de dermatologie, hôspital Edouard Herriot, Lyon, France.

Published: October 2020

Psoriasis typically affects young adults and therefore many women with a desire to become pregnant or already pregnant. In this particular situation, treatment can be a real challenge for some patients, especially in the case of severe forms. In addition to local treatments, which are generally well tolerated, UVB phototherapy and cyclosporin remain the first-line systemic treatments. Acitretin and methotrexate are contraindicated. Safety data regarding the administration of biologic agents during pregnancy, are reassuring, the main adverse event being immunosuppression of the newborn if treatment is not discontinued. Biologic agents should ideally be discontinued before pregnancy, but in case of absolute necessity, they can be maintained or even initiated during pregnancy. Overall, it is recommended that biologic agents should not be continued beyond the second trimester because of the risk of maternal-fetal infection. If a biologic agent should be initiated during pregnancy, tanercept or certolizumab will be preferred, because of their low transplacental passage and more extensive safety data.

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2020.3884DOI Listing

Publication Analysis

Top Keywords

biologic agents
12
safety data
8
initiated pregnancy
8
choix thérapeutique 
4
thérapeutique  médicaments
4
médicaments psoriasis
4
psoriasis grossesse
4
grossesse avant
4
avant pendant
4
pendant après
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!